American Society of Hirudotherapy

Ciprofloxacin-resistant Aeromonas infection following leech therapy for digit replantation: report of 2 cases

van Alphen NA, Gonzalez A, McKenna MC, McKenna TK, Carlsen BT, Moran SL (2014) · Journal of Hand Surgery · 2 patients

Case-level evidence: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCase reportInfections after leech therapy

Study Profile

Design
two-case report (Mayo Clinic Rochester, cases occurring within 4 months of each other)
Patients
2
Presentation and intervention
Leech therapy after unsuccessful digital replantation in patients with subsequent ciprofloxacin-resistant Aeromonas hydrophila infection
Outcome
Both cases successfully treated with ceftriaxone after failure of ciprofloxacin prophylaxis; documents emerging ciprofloxacin-resistant Aeromonas strains in replantation center setting
Follow-up duration
Infection resolution

Key Findings

  • Two ciprofloxacin-resistant Aeromonas cases within 4 months
  • Ceftriaxone successful as rescue antibiotic
  • Documents emerging resistance to first-line prophylaxis
  • Replantation centers should monitor local Aeromonas susceptibility
  • Antibiogram-guided prophylaxis selection recommended

Limitations

  • Only 2 cases - cannot quantify resistance prevalence
  • Single replantation center experience
  • Cannot determine if cases share common Aeromonas source
  • Limited microbiologic characterization of resistance mechanism
  • Cannot recommend universal protocol changes

Clinical Implications

van Alphen 2014 documents emerging ciprofloxacin-resistant Aeromonas at a major US replantation center, supporting periodic local antibiogram review and consideration of ceftriaxone as backup. For US clinicians under K040187, this Mayo Clinic case series reinforces antimicrobial stewardship principles and the dynamic nature of resistance profiles in leech-treated populations.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.